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BMD around the stems and implant stability. Although 
bisphosphonates increased the BMD more than calcitonin, 
there was no difference in implant stability. Indomethacin 
markedly decreased the periprosthetic BMD and implant 
stability. The main clinical significance of our study was 
the finding about the need to strictly avoid long-term use of 
high-dose nonsteroidal antiinflammatory drugs for patients 
who have major joint arthritis and a previous history of 
arthroplasty.
Introduction
Recent improvements in prosthesis design have encouraged 
surgeons to prefer cementless total hip arthroplasty (THA), 
even for elderly and osteoporotic patients [1]. Due to the 
poor bone quantity and density in osteoporotic patients, 
bone growth around the stem is insufficient compared to 
non-osteoporotic patients [2]. Adequate bone integration, 
reducing region-specific decreases in femoral bone density 
and early stability of implant fixation decrease the risk of 
early migration and loosening and then may reduce late 
loosening rates [1, 3].
Bisphosphonates and salmon calcitonin are well-known 
and effective inhibitors of bone resorption. Recent stud-
ies have shown that alendronate and risedronate signifi-
cantly inhibit the decrease of periprosthetic bone mineral 
density (BMD) and bone resorption in the proximal femur 
after cementless THA [4–6]. Calcitonin has also effectively 
enhanced the volume of the bone mass surrounding the 
prosthesis and also significantly increased the osseointegra-
tion rate after THA [7, 8].
Nonsteroidal antiinflammatory drugs (NSAIDs) are 
widely used analgesic agents for pain control in osteo-
arthritis, and they also play a major role in postoperative 
Abstract 
Background Many factors affect implant stability and 
periprosthetic bone mineral density (BMD) following 
total joint arthroplasty. We asked whether perioperative 
alendronate, risedronate, calcitonin and indomethacine 
administration altered (1) femoral stem shear strength 
and periprosthetic bone mineral density BMD in ovariec-
tomized rats and (2) whether there were differences in the 
effect of these drugs.
Methods Thirty overiectomized rats were divided into 
five groups and implanted with intramedullary mini-cor-
tical screws in the femur. Four groups were treated with 
alendronate, risedronate, salmon calcitonin and indometha-
cin for 4 weeks preoperatively and 8 weeks postoperatively.
Results Although alendronate and risedronate increased 
the periprosthetic BMD more than calcitonin, they did not 
alter implant fixation compared to calcitonin. Indometha-
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implant stability compared to all other groups.
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pain management in orthopedic surgery [9]. Indomethacin 
is one of the representative members of NSAIDs, has a 
well-known effect on bone formation and drastic inhibitory 
effects on fracture healing [9, 10]. Despite these facts, the 
effects of NSAIDs on implant stability and BMD around 
the stem after THA have not been widely investigated. 
The research mainly focused on the effect of NSAIDs on 
BMD values after long-term treatment and fracture healing 
[9–11].
Although these drugs are widely used in elderly arthro-
plasty patients alone or together, there has been no general 
overview study about these drugs. The aim of this study 
was to analyze and compare the effects of perioperative 
treatment with alendronate, risedronate, salmon calcitonin 
and indomethacin on periprosthetic BMD and fixation of 
the femoral stem in an ovariectomized rat model of osteo-
porosis; a group without any medical treatment was set as 
the control group.
Materials and methods
Thirty rats underwent bilateral ovariectomy 16 weeks 
before implantation and were randomly divided into five 
groups with each group comprising six rats. All were 
Wistar rats (260–280 g) and 24 weeks old as this age group 
has been shown to have the best osteoporotic response 
after overiectomy [12]. All rats were housed individually 
at 22 °C with a 12-h light: 12-h dark cycle in the Animal 
Research Facilities. The research procedures were in full 
compliance with Veterinary Medicine Deontology Regula-
tion 6.7.26 and the Helsinki Declaration of Animal Rights 
and had the approval of the Ethics Committee for Animal 
Research.
The first group of rats was assigned as the control group, 
and no other treatment was given to this group before and 
after implantation. The remaining four groups of ovariecto-
mized rats were treated with their assigned group protocol 
for 12 weeks, starting 4 weeks before the implantation and 
continuing for 8 weeks after the implantation. They were 
given: (1) [ALN] 0.2 mg/kg of alendronate, (2) [RSN] 
0.1 mg/kg of risedronate, (3) [CT] 2 IU/kg salmon calci-
tonin and (4) [IND] 4 mg/kg of indomethacin (Table 1). 
The ALN drug dosage was 0.1 mg/kg/day in a previous 
study with a similar experimental model [1]; we assumed 
the same 0.1 mg/kg as the daily dosage. This was 1 % of 
the therapeutic drug dose in humans. Therefore, we also 
used 1 % of the human therapeutic drug dose to deter-
mine the drug doses in rats for other drugs. All drugs were 
diluted with saline solution and applied subcutaneously 
once every 2 days as double the daily dosage.
After 4 weeks, animals were brought to the theatre 
inside the laboratory and anesthetized with a combination 
of 45 mg/kg ketamine hydrochloride and 5 mg/kg xylasine 
hydrochloride. After anesthetic agents had been admin-
istered intramuscularly, the surgical area was shaved and 
washed. A midline skin incision was made in the left knees 
of rats, and a standard medial parapatellar approach was 
performed. Using a 1.2-mm drill, the intercondylar notch 
of the left femur was drilled into the medullary cavity. All 
implants were 18 mm long and 1.3 mm in diameter (Syn-
thes: 1.3 mm self-taping screw) and implanted into the 
intramedullary cavity (Fig. 1a). At the end of the opera-
tion, the muscle and skins were closed in anatomical layers. 
There were no wound problems or infections in any of the 
rats after surgery. Drug application for the groups was con-
tinued for a further 8 weeks as mentioned above. All of the 
rats were killed 8 weeks after implantation with a combi-
nation of 60 mg/kg ketamine hydrochloride and 20 mg/kg 
xylasine hydrochloride given intramuscularly. Implanted 
femurs of the rats were carefully dissected and excised.
Periprosthetic BMDs of all rats were analyzed by using 
a Lunar DPX-IQ DXA (NY,USA) using Lunar’s Small Ani-
mal Software version 1.0 set in the HiRes (0.6 × 1.2 mm) 
Medium mode <0.5 kg. All of the dual-energy X-ray 
absorptiometry (DEXA) measurements were done from 
the distal metaphyseal region of implanted femurs. The 
periprosthetic BMD value was calculated as described in a 
previous study [9]. The BMD value of the screw was meas-
ured alone, then the difference between the mean BMD 
value and BMD value of the screw alone gave us the BMD 
around the stem. Direct anterior posterior X-rays of the 
femurs were also taken (Fig. 1b).
Before shear strength measurement, the distal ends of 
the dissected femurs were trimmed carefully in order to 
expose the head of the implant. A steel wire was folded 
Table 1  Treatment schedule of the study with 24-week-old Wistar rats (260–280 g)
Number of rats Preoperative medication (4 weeks) Implant Postoperative medication (8 weeks)
1. Group (control) 6 – + –
2. Group (alendroante) 6 0.2 mg/kg (once every 2 days) + 0.2 mg/kg (once every 2 days)
3. Group (risedronate) 6 0.1 mg/kg (once every 2 days) + 0.1 mg/kg (once every 2 days)
4. Group (salmon calcitonin) 6 2 IU/kg (once every 2 days) + 2 IU/kg (once every 2 days)
5. Group (indomethacine) 6 4 mg/kg (once every 2 days) + 4 mg/kg (once every 2 days)
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in half from both edges. The midportion of the wire was 
placed under the head of the screw circumferentially and 
secured there by twisting from both edges. The two oppo-
site free edges of the wires were connected to each other 
centrally above the head by the longitudinal direction of 
the screw. The proximal part of the dissected femur was 
secured inside the hole within the wooden block by using 
bone cement. The push-out strength was defined as the 
peak force occurring while the implant loosened from the 
bone [3]. The shear strength at the bone-implant interface 
was measured by applying a vertical load to the implant 
through the wire secured to the head of the screw. Shear 
strength measurements were done with a Lloyd-LR5 K 
(Fareham, UK) pressure test device. The pressure test 
device was used with a constant displacement speed of 
0.5 mm/min to measure the shear strength.
The present study was approved by the Animal Experi-
ments Local Ethics Committee prior to performing the 
study. Statistical analyses were performed with SPSS 13.0 
(SPSS Inc., Chicago, IL, USA) and were calculated as the 
median, mean and standard deviation for all groups. The 
comparison between groups was done with the Kruskal-
Wallis test, and the post hoc test was used to analyze the 
differences between groups. p values <0.05 were consid-
ered to indicate a statistically significant difference.
Results
Periprosthetic BMD and bone-implant shear strength 
results of the groups were calculated as the median, mean 
and standard deviation and are shown in Table 2. The bone 
mineral density of the ALN and RSN groups was signifi-
cantly higher than in the control group (p < 0.001). There 
was no significant difference between these two bisphos-
phonates in terms of the periprosthetic BMD values of the 
ALN and RSN groups (p > 0.05). The median peripros-
thetic BMD value of the ALN group was about 35 % higher 
than that in the control group (0.249 g/cm2). Compared 
with the control group, the CT group had significantly 
higher periprosthetic BMD values (p < 0.01). The peripros-
thetic BMD values of the ALN and RSN groups were sig-
nificantly greater than in the CT group (p < 0.001), and the 
median BMD value of this group was about 23 % lower 
than that in the ALN group. IND significantly decreased 
the periprosthetic BMD compared to the control (p < 0.01) 
and all other drug groups. The median periprosthetic BMD 
value of the IND group was about 20 % lower than in the 
control group. Boxplots for comparisons of the peripros-
thetic BMDs of the groups are shown in Fig. 2.
Compared with the control group, the ALN and RSN 
groups had significantly higher bone-implant shear strength 
(p < 0.001) and were about 29 % higher than in the con-
trol group. There was no significant difference between 
these two bisphosphonates (p > 0.05). The bone-implant 
shear strength of the salmon calcitonin group was sig-
nificantly greater than in the control group (p < 0.001). 
Although these two bisphosphanates had higher peripros-
thetic BMD values compared to the salmon calcitonin, 
regarding the bone-implant shear strength, there was no 
statistical difference between these two bisphosphonates 
Fig. 1  Knee of an overiectomized rat after implantation of a 1.3-mm 
intramedullary screw (a) and X-ray of the implanted femur of the 
overiectomized rat (b)
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and salmon calcitonin (p > 0.05). Regarding IND, it sig-
nificantly decreased bone-implant shear strength com-
pared to the control (p < 0.01) and all other drug groups 
(p < 0.001). The median value of the indomethacin group 
was about 26 % lower than that in the control group. Box-
plots for comparisons of the bone-implant shear strength of 
the groups are shown in Fig. 3.
Discussion
In the present study, we aimed to investigate the effects of 
clinically well-known anti-osteolytic agents on the integrity 
of the implant-bone interface. A well-known analgesic drug 
with established anti-osteoblastic activity was also added 
to the study design for both observations of its effects on 
the shear strength and BMD around the implant. The cur-
rent study clearly demonstrates the additive effect of the 
bisphosphonates studied in the current model on BMD and 
implant shear strength. The representative NSAID “indo-
methacin” was also clearly demonstrated to have detrimen-
tal effects on BMD and implant shear strength.
Patients who need total hip arthroplasty (THA) are 
mainly eldery and have coexisting osteoporosis, so they are 
vulnerable to the occurrence of negative factors leading to 
persistent pain, which may lead to the need for undesirable 
revision surgery [7]. After a cementless total hip arthro-
plasty, the integrity of the implant-bone interface is among 
the main determining factors of implant survival. Bone 
resorption around the periprosthetic area and consequent 
shifting of the implant would be negative factors for the 
long-term results [1, 7]. Hence, recent research has mostly 
focused on improving biological fixation for long-term sur-
vival of implants by preventing osteolysis and osteoporotic 
bone loss at the periprosthectic area [1, 5, 6, 8, 13, 14]. In 
real life, the implant-bone interface occurs in the metaphy-
seal area filled with cancellous bone. Overiectomized rat 
models are associated with cancellous bone loss [1, 2]. For 
Table 2  Periprosthetic bone mineral density and bone-implant shear strength of the groups with the mean and median values after 12 weeks 
(4 weeks before and 8 weeks after implantation) treatment
The values are given as the mean ± SD and the median with the minimum-maximum values in parentheses
Bone mineral density (g/cm2) Bone-implant shear strength (N)
Mean Median Mean Median
Control 0.250 ± 0.019 0.249 (0.229–0.278) 6.99 ± 0.76 6.98 (5.89–8.11)
Alendronate 0.381 ± 0.022 0.384 (0.346–0.409) 9.65 ± 1.07 9.77 (8.12–11.23)
Risedronate 0.372 ± 0.028 0.370 (0.332–0.411) 9.69 ± 1.13 9.84 (8.02–11.23)
Salmon calcitonin 0.302 ± 0.030 0.294 (0.276–0.356) 9.27 ± 1.15 9.00 (7.71–10.98)
Indomethacine 0.203 ± 0.019 0.198 (0.181–0.231) 5.14 ± 0.69 5.17 (4.12–6.13)
Fig. 2  Boxplots for comparisons of the periprosthetic bone mineral 
density (g/cm2) of the groups after 12 weeks (4 weeks preoperatively, 
8 weeks postoperatively) of treatment. The line in the middle of the 
box represents the median for each group
Fig. 3  Boxplots for comparisons of the bone-implant shear strength 
(N) of the groups after 12 weeks (4 weeks preoperatively, 8 weeks 
postoperatively) of treatment. The line in the middle of the box repre-
sents the median for each group
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this reason, animal study models based on ovariectomized 
rats provide a model similar to a postmenopausal osteo-
porotic bone host [1, 13, 14]. To replicate the clinical situ-
ation, we therefore preferred an overiectomized rat model 
for our study design, and an implant was also placed in the 
metaphyseal area.
Clinical and experimental studies have shown that bis-
phosphonates decrease periprosthetic bone loss [4, 5, 13–
15] and increase implant stability [1, 13, 16]. Although 
risedronate and alendronate were shown to inhibit peripros-
thetic bone loss around the femoral component and increase 
implant stability after cementless total hip arthroplasty [4–
6, 15, 17], no experimental studies have compared them. 
There was no statistical difference between their positive 
outcomes, so we concluded that perioperative use of ALN 
and RSN improved outcomes after cementless THA with-
out one being superior to the other.
Salmon calcitonin is the other most commonly used ant-
iosteoporotic drug beside bisphosphonates. Several stud-
ies showing that calcitonin decreases bone loss after bone 
fracture and cementless THA [7, 8, 18, 19]. Duarte et al. 
[19, 20]  demonstrated that CT administration resulted in 
an increase in bone density around the implant, but this 
increase was not significant, and ALN therapy might be 
effective in the prevention of bone loss around implants in 
overiectomized rats. The present comparative study sup-
ported a previous comparative study concluding the effect 
of ALN on osseointegration of implants is superior to 
salmon CT [7]. Chen et al. [7] concluded that ALN might 
be a better choice than salmon CT in order to maintain bet-
ter stability of the prosthesis because of their histological 
findings. This suggestion is disputable, as the bone integra-
tion at the entire implant could not be measured by histo-
logical studies, and these studies provide limited informa-
tion regarding bone-implant fixation. In the present study, 
although ALN and RSN had slightly higher mean shear 
strength compared to salmon CT, no significant difference 
was detected. Thus, they are both beneficial for osteoporo-
tic patients in need of a total joint arthroplasty, and no one 
of these two major osteoporosis drug groups is superior 
regarding the implant stability.
Because of their analgesic and antiinflammatory effects, 
nonsteroidal antiinflammatory medications are among the 
most commonly prescribed drugs [21]. They are widely 
used by patients who have undergone major joint arthro-
plasties before and after the surgical procedure. However, 
there have been few mechanical studies on the effect of 
NSAIDs on implant fixation in experimental animal mod-
els, and these studies were mainly done in the 1990s [22–
24]. Contradictions in these studies emphasized the neces-
sity of further investigations of NSAIDs [21]. Trancik et al. 
[23] concluded that IND, aspirin and ibuprofen decreased 
bone ingrowth in a dose-related fashion up to 8 weeks. IND 
was shown to decrease the cancellous bone volume in ove-
riectomized rats up to 24 weeks. Dimmen et al. [9] reported 
a 14 % decrease in periprosthetic BMD in their intramed-
ullary implanted fractured tibia model in rats after 3-week 
treatment.
However, Cook et al. [22] suggested that perioperative 
administration of indomethacin did not significantly affect 
the attachment strength or bone ingrowth into implants in 
the long-term period. The results of this study were con-
tradictory to our and other studies. In the present study, 
IND significantly decreased the periprosthetic BMD value 
and implant stability. In addition to possible reasons for 
the contradictory results, there are some limitations to this 
study and to using its results for cementless THA in elderly 
patients. These include the transverse bicortical placement 
of the implants, the choice of the cortical diaphyseal region 
for implantation and lack of overiectomy surgery in the 
experimental rats.
There are some limitations to this study. First, it was an 
experimental study, which limits the direct application of 
the results to clinical practice, like in any other experimen-
tal study. Second, there was no histopathological exami-
nation because of the detrimental effect of mechanical 
examination on tissue integrity and the inadequate number 
of experimental animals. In addition, bisphosphonates are 
also used with breaks by the patients. As we examined the 
continuous use of these drugs, the effect of taking breaks 
in the use of these drugs could not be determined. Finally, 
the relative shortness of the treatment period in the present 
study did not provide any information about the effect of 
these drugs in the long-term period.
In summary, although bisphosphonates increased the 
BMD around the stem more than salmon calcitonin, there 
was no difference in implant stability; thus, they are both 
beneficial for osteoporotic patients in need of total joint 
arthroplasty. We concluded that clinicians have to strictly 
avoid the long-term use of high-dose NSAIDs for osteo-
porotic patients who have major joint arthritis and previ-
ous arthroplasty history. Alternative treatment modalities 
in pain management can be applied in the postoperative 
period to decrease the usual NSAID dose. However, as 
data on this issue are limited, further studies with different 
doses and treatment durations are needed to reach generally 
accepted conclusions about the use of NSAIDs in arthro-
plasty patients before and after surgical procedures.
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